Tickers

1. Composite Trajectory Verdict

For a pre-commercial nuclear technology developer, the cash flow statement and balance sheet carry the most weight because the business model depends on raising external capital to fund development through the early 2030s; the income statement is dominated by non-cash equity compensation and warrant remeasurement that obscure the underlying cash economics.

Composite Trajectory: Mixed

The balance sheet improved dramatically due to the April 2026 IPO, which raised ~$1.1 billion net proceeds, eliminated all warrant liabilities ($274 million at Dec 31 2025) and mezzanine equity ($2.07 billion), and flipped total equity from a $1.22 billion deficit to a $2.10 billion surplus (10-Q 2026-06-30, Condensed Balance Sheets). However, the earnings trajectory is deteriorating: six-month operating loss widened 155% YoY to $176 million while revenue grew only 132% (10-Q 2026-06-30, Condensed Statements of Operations). Operating cash burn nearly tripled to $165 million for the first half of 2026 versus $62 million in the prior year (10-Q 2026-06-30, Condensed Statements of Cash Flows). The cash flow statement therefore shows a sharply negative operating trend offset by a one-time financing inflow.

2. Red Flags

• Operating cash burn accelerating faster than revenue: Net cash used in operating activities rose 166% YoY to $164.6 million for six months ended June 30 2026, while total revenue and grant income grew 132% (10-Q 2026-06-30, Condensed Statements of Cash Flows; Condensed Statements of Operations).
• Equity-based compensation explosion: Total equity/unit-based compensation jumped to $43.9 million for six months ended June 30 2026 from $6.4 million in the prior year, driven by IPO-related option grants (10-Q 2026-06-30, MD&A Results of Operations; Note 11).
• Mark-to-market warrant volatility: Six-month mark-to-market loss on warrant liabilities was $114.5 million in 2026 versus $39.5 million in 2025, though Q2 alone showed a $5.6 million loss versus $50.5 million a year earlier (10-Q 2026-06-30, Condensed Statements of Cash Flows; Note 2 Other Income).
• Extreme customer concentration: The DOE accounted for 90.9% of six-month 2026 revenue and grant income; Dow accounted for 4.4% (10-Q 2026-06-30, Note 2 Certain Significant Risks).
• Revenue recognition vs. cash collection gap: Unbilled receivables and contract assets grew to $75.4 million at June 30 2026 from $41.5 million at Dec 31 2025, while accounts receivable rose to $40.8 million from $32.9 million (10-Q 2026-06-30, Condensed Balance Sheets).
• No debt but massive dilution: The IPO issued 50.9 million Class A shares; 118.9 million Class B shares and 7.6 million options remain outstanding (10-Q 2026-06-30, Note 12).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Six-month GAAP net loss widened 174% YoY to $271.6 million (10-Q 2026-06-30, Condensed Statements of Operations). Operating loss grew 155% to $176.1 million as total operating expenses rose 146% to $274.2 million, outpacing the 132% increase in total revenue and grant income to $98.0 million. The expense surge was driven by direct costs (+126% to $152.0 million) and SG&A (+115% to $121.9 million), both heavily inflated by equity-based compensation ($43.9 million combined vs. $6.4 million). Non-GAAP adjusted net loss also deteriorated, rising to $113.2 million from $51.7 million (10-Q 2026-06-30, MD&A Non-GAAP Financial Measures). Grant income declined slightly (-4% to $8.0 million) while services revenue grew 165% to $90.0 million, almost entirely from the ARDP cost-share agreement with DOE.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Core operating cash generation worsened sharply: net cash used in operating activities was $164.6 million for six months ended June 30 2026 versus $61.8 million in the prior year (10-Q 2026-06-30, Condensed Statements of Cash Flows). Investing outflows surged to $239.6 million from $18.7 million, driven by $316.5 million of investment purchases and $106.3 million of capital expenditures (partially offset by $130.9 million of maturities and $52.3 million of grant reimbursements). The $1.09 billion net financing inflow came almost entirely from the IPO ($1.10 billion net proceeds), a one-time event. Excluding the IPO, free cash flow (operating + investing) was -$404.2 million versus -$80.5 million a year earlier.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

The April 2026 IPO transformed the balance sheet. Cash and cash equivalents rose to $1.15 billion from $458.9 million at Dec 31 2025; short-term investments grew to $489.8 million from $304.9 million (10-Q 2026-06-30, Condensed Balance Sheets). Total assets nearly doubled to $2.26 billion from $1.21 billion. All warrant liabilities ($274.2 million) and mezzanine equity ($2.07 billion) were eliminated. Total liabilities fell to $159.6 million from $369.0 million. Total equity (including non-controlling interest) swung from a $1.22 billion deficit to a $2.10 billion surplus. Property and equipment (net) more than doubled to $119.1 million from $50.1 million, reflecting TX-1 construction spend. The improvement is almost entirely financing-driven; operating liabilities (accounts payable, accrued liabilities) grew modestly.

6. Data Gaps

• Standalone Q1 2026 quarterly results (the 10-Q for period 2026-03-31 is truncated in the provided materials; only MD&A fragments are visible).
• Full-year 2025 audited financials (only six-month 2025 interim data is available for YoY comparison).
• Quarterly trend for 2026 beyond Q2 (only two quarters maximum would be available even with complete filings).
• Annual YoY comparison for any metric (no 10-K provided).
• Breakdown of capital expenditures by project (TX-1 vs. other) beyond the aggregate figure.
• Detailed ARDP budget period status and remaining reimbursable amounts beyond the narrative description.